Activated Clotting Time Testing Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

The Activated Clotting Time Testing Market is Segmented by Product (ACT Analyzers and Consumables), Test Type (High-Range ACT Tests and Low-Range ACT Tests), Application, End User, Technology, and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Activated Clotting Time Testing Market Size and Share

Activated Clotting Time Testing Market Size
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Activated Clotting Time Testing Market Analysis by Mordor Intelligence

The Activated Clotting Time Testing Market size is expected to grow from USD 1.34 billion in 2026 to USD 1.44 billion in 2027 and is forecast to reach USD 2.09 billion by 2032 at 7.78% CAGR over 2027-2032.

Activated clotting time testing supports immediate heparin management during cardiovascular surgery, percutaneous coronary intervention, extracorporeal membrane oxygenation, and hemodialysis. The movement of selected cardiovascular procedures into ambulatory settings is widening the installed base required for near-patient anticoagulation testing. Suppliers are responding by linking analyzers to recurring cartridge demand, developing portable systems, and improving connectivity across hospital networks. These conditions support demand for the activated clotting time testing market while placing greater weight on clinical validation, workflow fit, and total cost of ownership.

Key Report Takeaways

  • By product, consumables held 87.99% of the market share in 2026 and are projected to expand at a 9.17% CAGR through 2032.
  • By test type, high-range ACT tests held 65.34% of the market share in 2026 and are projected to expand at an 8.23% CAGR through 2032.
  • By application, hemodialysis was the largest application in 2026, capturing 48.31% in 2026, while extracorporeal membrane oxygenation recorded the highest projected CAGR at 10.19% through 2032.
  • By end user, hospitals held 54.31% of the market share in 2026, while ambulatory surgical centers are projected to expand at a 10.02% CAGR through 2032.
  • By technology, point-of-care testing systems held 68.21% of the market share in 2026, while portable testing systems are projected to expand at a 9.45% CAGR through 2032.
  • By geography, North America held 39.89% of the market share in 2026, while Asia-Pacific is projected to expand at a 9.65% CAGR through 2032.

Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.

Activated Clotting Time Testing Market Segment Analysis

By Product:

Consumables Sustain the Dominant Revenue Engine

Consumables commanded 87.99% of the market share in 2026 and are projected to grow at a 9.17% CAGR through 2032. Their position reflects the repeated cartridge use required during cardiac surgery and other anticoagulation-managed procedures. Each test requires a specialized consumable, so routine clinical use produces recurring demand after an analyzer is installed. Hospitals also tend to validate their procedures with a particular activator chemistry. Changing a consumable supplier can require clinical and operational revalidation. This makes the consumables category the principal revenue engine in the activated clotting time testing industry.

ACT analyzers account for a smaller value base, but they anchor the installed base that supports later cartridge demand. Suppliers can use instrument pricing to secure long-term recurring revenue rather than seek the full margin at the point of capital sale. Haemonetics reported that its hemostasis management revenue rose more than 20% year over year in fiscal 2026, supported by disposable use after capital placements. This model shifts buyer attention toward total cost of ownership, service, and continuity of supply. Procurement decisions remain closely tied to cartridge economics. The activated clotting time testing market therefore depends on both capital placement and dependable consumable pull-through.

Need more granular breakdown of segment shares?

Get tailored market insights for your requirements.

Activated Clotting Time Testing Market Share by Product, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Activated Clotting Time Testing Market Share by Product, 2026

By Test Type:

High-Range ACT Tests Define the Clinical Standard

High-range ACT tests held 65.34% of the market share in 2026 and are forecast to expand at an 8.23% CAGR through 2032. These tests are used where high-dose heparin protocols are common, especially in cardiopulmonary bypass. Cardiac surgery teams have historically used an ACT threshold above 480 seconds during bypass. However, evidence is prompting closer review of the specific threshold used with each device. The segment remains central because major cardiac procedures require rapid and repeated anticoagulation measurements.

The 2025 randomized study of 1,021 cardiac surgery patients found that a target of at least 400 seconds produced comparable transfusion outcomes and lower postoperative blood loss. This change in clinical debate does not necessarily lower demand for testing. Instead, it can increase the need for local validation and repeated measurement while clinicians establish safe operating protocols. Low-range ACT tests remain important in PCI, hemodialysis, and atrial fibrillation ablation. A 2025 study in cryoablation found meaningful differences in target attainment between high-range and low-range assays. The activated clotting time testing industry must therefore support test selection that aligns with clinical setting and heparin regimen.

By Application:

ECMO Accelerates While Hemodialysis Anchors the Base

Hemodialysis was the largest application in 2026, holding 48.31%. Hemodialysis supports a broad and recurring testing base because anticoagulation decisions are made across repeated treatment sessions. ACT targets in this setting guide heparin titration during renal replacement therapy. This recurring use differs from the episodic demand associated with major surgery. It gives the activated clotting time testing market a stable base of routine procedures.

Extracorporeal membrane oxygenation is projected to grow at a 10.19% CAGR through 2032. ECMO is growing as treatment expands beyond traditional rescue use into cardiogenic shock, pulmonary embolism, and perioperative support. A systematic review found that ACT remains widely used because it is available at the bedside and produces rapid results[2]. Cardiovascular surgery continues to consume multiple tests per case, even where some bypass volumes are steady. Interventional cardiology and critical care add further demand as outpatient procedures and intensive care protocols evolve. These combined application settings keep the activated clotting time testing market tied to both high-acuity and chronic care workflows.

By End User:

Hospitals Lead While Ambulatory Centers Expand

Hospitals accounted for 54.31% of the market share in 2026. They remain the core setting for high-acuity cardiovascular surgery, complex PCI, ECMO, and intensive care. These procedures often require access to surgical backup, blood bank services, and specialized staff. Hospitals are also better positioned to operate multi-department quality systems for point-of-care testing. Their broad clinical scope protects their leading role in the activated clotting time testing market.

Ambulatory surgical centers are the fastest-growing end-user setting, growing at a CAGR of 10.02% from 2027 to 2032. The migration of selected cardiovascular procedures into outpatient settings is a key factor behind this development. These facilities require portable and simple systems that can function without a large central laboratory footprint. Clinical laboratories retain a role in preoperative screening and result confirmation. Specialty clinics may add a smaller pool of demand where low-range anticoagulation monitoring is appropriate. Suppliers in the activated clotting time testing market that combine compact instruments with quality documentation are positioned to address these changing care sites.

Segment this market the way your business does.

Get tailored market insights for your requirements.

Activated Clotting Time Testing Market Share by End User, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

By Technology:

Point-of-Care Systems Dominate While Portability Advances

Point-of-care testing systems held 68.21% of the market share in 2026. Their leading position is based on the need for real-time results during procedures where immediate heparin decisions are required. Established platforms are widely used in cardiac operating rooms and catheterization laboratories. The clinical value is not only speed but also the ability to repeat testing at the bedside as conditions change. This makes near-patient testing the core technology base in the activated clotting time testing industry.

Portable testing systems are forecast to grow at a 9.45% CAGR through 2032. Battery-operated and compact formats can support testing in cardiac intensive care units, mobile surgical units, rural referral centers, and hospitals with limited laboratory infrastructure. Siemens Healthineers launched its CN-3000 and CN-6000 hemostasis systems in the United States in September 2026, highlighting continuing demand for smaller footprints and integrated testing workflows. Integrated monitoring platforms are also gaining attention where cardiac programs seek broader coagulation oversight. The resulting technology direction in the activated clotting time testing market favors connectivity, portability, and validated performance in addition to basic assay speed.

Geography Analysis

North America

North America held 39.89% of the market share in 2026. The region benefits from a large base of cardiac operating rooms, catheterization laboratories, and ECMO centers. U.S. coronary revascularization activity sustains demand for frequent anticoagulation testing. The continued migration of selected procedures to ambulatory settings creates a need for portable systems and cartridge workflows outside the traditional operating room. Werfen’s 2025 North American commercialization of the ACL TOP Family 70 Series shows the importance of centralized quality management for multi-site laboratories. Regulatory review by the U.S. Food and Drug Administration and laboratory quality requirements remain influential in system selection. Canada adds demand through established cardiac programs, while Mexico presents a developing private-hospital opportunity. These structural conditions preserve North America’s leading role in the activated clotting time testing market.

Asia-Pacific

Asia-Pacific is projected to expand at a 9.65% CAGR through 2032, the fastest regional rate in the activated clotting time testing market. India’s 2,200 catheterization laboratories remain well below the estimated 6,500 required, creating demand for broader access to interventional cardiac care. Expansion into district hospitals and secondary cities will require equipment, training, and repeat-test consumables. Japan remains an important technology market, where SEKISUI Medical launched the compact CP3000α analyzer in April 2025. Siemens Healthineers and Sysmex began delivering CN-6000 and CN-3000 systems in Japan in October 2025. Mature cardiac systems in South Korea and Australia coexist with newer dedicated cardiac programs in Southeast Asia. This mix of mature adoption and new capacity gives suppliers room to offer both advanced connected platforms and practical portable systems.

Europe, the Middle East and Africa, and South America

Europe is a mature regional group with high-volume cardiac programs, while activity in several Eastern European countries is increasing. The European Union’s In Vitro Diagnostic Regulation requires many hemostasis devices in Class C to meet full compliance requirements by 2028. This compliance factor can favor manufacturers with the resources to manage recertification and documentation. The Middle East combines new cardiac infrastructure in Gulf Cooperation Council countries with limited capacity in parts of sub-Saharan Africa, where cardiac surgery programs remain below clinical need. South America offers demand through Brazil’s public hospital network but faces procurement variation and currency-related purchasing pressure. These regions are mixed geographic segments, so local service, training, and price-sensitive offers can be as important as device features. Growth in these areas depends on how providers manage access, reimbursement, and regulatory compliance.

Activated Clotting Time Testing Market Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Market Concentration

Activated Clotting Time Testing Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

The activated clotting time testing market is moderately consolidated around established diagnostics and hemostasis suppliers, including Werfen, Abbott Laboratories, Siemens Healthineers, and Haemonetics. Their installed-base positions are strongest in high-volume cardiac surgery and catheterization laboratory settings. Competition is shaped by the relationship between capital instruments and recurring consumables. Suppliers may accept pricing pressure on analyzers to build a durable cartridge customer base. This business model makes service quality, workflow integration, and supply reliability central to account retention.

Werfen commercialized the ACL TOP Family 70 Series in North America in March 2025 after U.S. FDA clearance and Health Canada licensure. The system uses HemoHub Intelligent Data Manager to support centralized quality control across laboratory networks. Haemonetics reported more than 20% year-over-year growth in fiscal 2026 hemostasis management revenue, supported by TEG 6s disposable use following capital placements. Siemens Healthineers launched the CN-3000 and CN-6000 in the United States in September 2026, with a smaller footprint and multiple hemostasis testing methods. These actions show a move toward connected data management, compact design, and broader hemostasis portfolios.

Smaller companies can compete through specialized applications and focused clinical positioning. HemoSonics received U.S. FDA 510(k) clearance in September 2025 to expand the Quantra Hemostasis System with QStat Cartridge into peripartum obstetric procedures. Alternative heparin-monitoring methods may also shape competition in ECMO and critical care when clinical programs seek more than one monitoring approach. However, validated workflows and cartridge supply agreements make rapid replacement of existing ACT platforms difficult. The competitive position of leading suppliers therefore rests on installed base coverage, clinical support, software connectivity, and recurring consumables. The activated clotting time testing market remains open to specialized innovation, but broad platform conversion requires substantial validation and account support.

Activated Clotting Time Testing Industry Leaders

  1. Abbott Laboratories

  2. Haemonetics Corporation

  3. Medtronic plc

  4. Siemens Healthineers AG

  5. Werfen

  6. *Disclaimer: Major Players sorted in no particular order

Activated Clotting Time Testing Market Companies Covered in this Report

  • Abbott Laboratories
  • Accriva Diagnostics
  • bioMérieux
  • Danaher
  • Diagnostica Stago SA
  • Roche
  • Haemonetics
  • Helena Laboratories
  • HORIBA
  • Instrumentation Laboratory Company
  • International Technidyne Corporation
  • Medtronic
  • QIAGEN
  • SEKISUI MEDICAL CO. LTD
  • Mindray
  • Siemens Healthineers
  • Sienco
  • Sysmex
  • Thermo Fisher Scientific
  • Werfen

Recent Industry Developments in Activated Clotting Time Testing Market

  • November 2026: Werfen received U.S. FDA 510(k) clearance for the ROTEM sigma complete cartridge for assessing perioperative hemorrhage and thrombosis in trauma patients. This extends the ROTEM sigma viscoelastic testing system's U.S. indications beyond cardiovascular surgery and liver transplantation, significantly expanding Werfen's addressable procedure base in emergency and perioperative bleeding management.
  • September 2026: Siemens Healthineers launched the CN-3000 and CN-6000 automated hemostasis analyzers in the United States for mid- and high-volume laboratories. The compact platform consolidates clotting, chromogenic, immunoassay, and platelet aggregation methodologies onto a system reported to be up to 60% smaller than comparable alternatives, with up to 13 hours of walkaway time and connectivity to Atellica Data Manager for multisite oversight.

Table of Contents for Activated Clotting Time Testing Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Cardiovascular Surgery and Interventional Cardiology Volumes
    • 4.2.2 Increasing Point-of-Care Testing Adoption
    • 4.2.3 Growth in ECMO and Extracorporeal Therapies
    • 4.2.4 Expansion of Cardiac Care Infrastructure in Asia-Pacific
    • 4.2.5 Increasing Demand for Cartridge-Based, Low-Volume Testing
    • 4.2.6 Increasing Integration of ACT Devices With Hospital Information Systems
  • 4.3 Market Restraints
    • 4.3.1 High Analyzer and Recurring Consumables Costs
    • 4.3.2 Variability in ACT Results Across Devices and Activators
    • 4.3.3 Limited Standardization of ACT Reference Ranges
    • 4.3.4 Reimbursement and Procurement Fragmentation in Emerging Markets
  • 4.4 Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter’s Five Forces
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Suppliers
    • 4.7.3 Bargaining Power of Buyers
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value in USD)

  • 5.1 By Product
    • 5.1.1 ACT Analyzers
    • 5.1.2 Consumables
  • 5.2 By Test Type
    • 5.2.1 High-Range ACT Tests
    • 5.2.2 Low-Range ACT Tests
  • 5.3 By Application
    • 5.3.1 Cardiovascular Surgery
    • 5.3.2 Interventional Cardiology
    • 5.3.3 Extracorporeal Membrane Oxygenation
    • 5.3.4 Hemodialysis
    • 5.3.5 Critical Care
  • 5.4 By End User
    • 5.4.1 Hospitals
    • 5.4.2 Ambulatory Surgical Centers
    • 5.4.3 Clinical Laboratories
    • 5.4.4 Specialty Clinics
  • 5.5 By Technology
    • 5.5.1 Point-of-Care Testing Systems
    • 5.5.2 Laboratory-Based Testing Systems
    • 5.5.3 Portable Testing Systems
    • 5.5.4 Integrated Monitoring Platforms
  • 5.6 By Geography
    • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
    • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
    • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 Japan
    • 5.6.3.3 India
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
    • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
    • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
    • 6.3.1 Abbott Laboratories
    • 6.3.2 Accriva Diagnostics
    • 6.3.3 bioMérieux SA
    • 6.3.4 Danaher Corporation
    • 6.3.5 Diagnostica Stago SA
    • 6.3.6 F. Hoffmann-La Roche Ltd
    • 6.3.7 Haemonetics Corporation
    • 6.3.8 Helena Laboratories Corporation
    • 6.3.9 HORIBA Ltd
    • 6.3.10 Instrumentation Laboratory Company
    • 6.3.11 International Technidyne Corporation
    • 6.3.12 Medtronic plc
    • 6.3.13 QIAGEN N.V.
    • 6.3.14 SEKISUI MEDICAL CO. LTD
    • 6.3.15 Shenzhen Mindray Bio-Medical Electronics Co. Ltd
    • 6.3.16 Siemens Healthineers AG
    • 6.3.17 Sienco, Inc.
    • 6.3.18 Sysmex Corporation
    • 6.3.19 Thermo Fisher Scientific Inc.
    • 6.3.20 Werfen

7. Market Opportunities & Future Outlook

  • 7.1 White-space and Unmet-need Assessment

Global Activated Clotting Time Testing Market Report Scope

As per the report’s scope, activated clotting time testing covers point-of-care and laboratory-based assessment of whole-blood clotting time to support heparin anticoagulation management during procedures and care settings that require timely clinical decisions.

The activated clotting time testing market is segmented by product, test type, application, end user, and technology. By product, the market is segmented into ACT analyzers and consumables. By test type, the market is segmented into high-range ACTs and low-range ACTs. By application, the market is segmented into cardiovascular surgery, interventional cardiology, extracorporeal membrane oxygenation, hemodialysis, and critical care. By end user, the market is segmented into hospitals, ambulatory surgical centers, clinical laboratories, and specialty clinics. By technology, the market is segmented into point-of-care testing systems, laboratory-based testing systems, portable testing systems, and integrated monitoring platforms.

By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The market report also covers estimated market sizes and trends for 17 countries across major regions worldwide. The report offers market size and forecasts in value (USD) for the above segments.

Segmentation Overview

By Product
Activated Clotting Time Testing Market segmentation breakdown
ACT Analyzers
Consumables
By Test Type
Activated Clotting Time Testing Market segmentation breakdown
High-Range ACT Tests
Low-Range ACT Tests
By Application
Activated Clotting Time Testing Market segmentation breakdown
Cardiovascular Surgery
Interventional Cardiology
Extracorporeal Membrane Oxygenation
Hemodialysis
Critical Care
By End User
Activated Clotting Time Testing Market segmentation breakdown
Hospitals
Ambulatory Surgical Centers
Clinical Laboratories
Specialty Clinics
By Technology
Activated Clotting Time Testing Market segmentation breakdown
Point-of-Care Testing Systems
Laboratory-Based Testing Systems
Portable Testing Systems
Integrated Monitoring Platforms
By Geography
Activated Clotting Time Testing Market segmentation breakdown
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Activated Clotting Time Testing Market segmentation breakdown
By Product ACT Analyzers
Consumables
By Test Type High-Range ACT Tests
Low-Range ACT Tests
By Application Cardiovascular Surgery
Interventional Cardiology
Extracorporeal Membrane Oxygenation
Hemodialysis
Critical Care
By End User Hospitals
Ambulatory Surgical Centers
Clinical Laboratories
Specialty Clinics
By Technology Point-of-Care Testing Systems
Laboratory-Based Testing Systems
Portable Testing Systems
Integrated Monitoring Platforms
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America

Key Questions Answered in the Report

What is driving growth in activated clotting time testing?

The need for real-time heparin monitoring during cardiac surgery, PCI, ECMO, and hemodialysis supports demand. The category is forecast to grow at a 7.78% CAGR from 2027 to 2032.

Which product category generates the most revenue?

Consumables led with an 87.99% share in 2026 and are forecast to grow at a 9.17% CAGR through 2032 because each procedure requires repeat cartridge use.

Why are point-of-care systems important for ACT testing?

Point-of-care systems held a 68.21% share in 2026 because they provide timely anticoagulation results during procedures that require immediate decisions.

Which application is growing fastest?

ECMO is the fastest-growing application at a 10.19% CAGR through 2032, supported by broader use in cardiogenic shock, pulmonary embolism, and perioperative care.

Which region has the strongest growth outlook?

Asia-Pacific is forecast to grow at a 9.65% CAGR through 2032 as cardiac care infrastructure expands across India, Japan, and Southeast Asia.

What can limit adoption of ACT platforms?

High analyzer and cartridge costs, device-to-device variability, and the need for local protocol validation can slow adoption, especially in price-sensitive systems.

Page last updated on: